GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » EV-to-Revenue

Kazia Therapeutics (Kazia Therapeutics) EV-to-Revenue

: (As of Today)
View and export this data going back to 1999. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kazia Therapeutics's enterprise value is $6.81 Mil. Kazia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil. Therefore, Kazia Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Kazia Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Kazia Therapeutics was 690.92. The lowest was -1.61. And the median was 9.41.

KZIA's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.58
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Kazia Therapeutics's stock price is $0.37. Kazia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Therefore, Kazia Therapeutics's PS Ratio for today is .


Kazia Therapeutics EV-to-Revenue Historical Data

The historical data trend for Kazia Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 9.40 - -

Kazia Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.40 - - - -

Competitive Comparison

For the Biotechnology subindustry, Kazia Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kazia Therapeutics EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's EV-to-Revenue falls into.



Kazia Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Kazia Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6.814/0
=

Kazia Therapeutics's current Enterprise Value is $6.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kazia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kazia Therapeutics  (NAS:KZIA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Kazia Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.37/0
=

Kazia Therapeutics's share price for today is $0.37.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kazia Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics (Kazia Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Executives
Josiah T Austin director, 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204